Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Total Liabilities for 7 consecutive years, with $163.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 14.56% to $163.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $163.1 million through Dec 2025, up 14.56% year-over-year, with the annual reading at $163.1 million for FY2025, 14.56% up from the prior year.
  • Total Liabilities for Q4 2025 was $163.1 million at Kymera Therapeutics, up from $155.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $189.3 million in Q1 2021, with the low at $113.0 million in Q4 2022.
  • Average Total Liabilities over 5 years is $149.9 million, with a median of $149.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 101.81% in 2021, then decreased 29.04% in 2022.
  • Over 5 years, Total Liabilities stood at $146.3 million in 2021, then decreased by 22.76% to $113.0 million in 2022, then surged by 60.01% to $180.8 million in 2023, then decreased by 21.22% to $142.4 million in 2024, then rose by 14.56% to $163.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $163.1 million, $155.8 million, and $159.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.